MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 314230 | Name: Lucinactant

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lucinactant (trade name Surfaxin) is a liquid medication used to treat Infant Respiratory Distress Syndrome in infants.[1] It was approved for use in the United States by the U.S. Food and Drug Administration (FDA) on March 6, 2012. (Source: http://en.wikipedia.org/wiki/Lucinactant)

Chemical Structure

Lucinactant
Lucinactant
CAS#825600-90-6

Theoretical Analysis

MedKoo Cat#: 314230

Name: Lucinactant

CAS#: 825600-90-6

Chemical Formula: C128H242N26O24

Exact Mass: 2527.8515

Molecular Weight: 2529.45

Elemental Analysis: C, 60.78; H, 9.64; N, 14.40; O, 15.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Surfaxin
IUPAC/Chemical Name
L-Lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysine, acetate
InChi Key
OSPNFKYGOFXGBX-YWWKUQGPSA-N
InChi Code
InChI=1S/C126H238N26O22.C2H4O2/c1-69(2)53-90(137-106(153)85(132)43-33-38-48-127)114(161)145-98(61-77(17)18)122(169)149-99(62-78(19)20)118(165)141-91(54-70(3)4)110(157)133-86(44-34-39-49-128)107(154)138-95(58-74(11)12)115(162)146-103(66-82(27)28)123(170)150-100(63-79(21)22)119(166)142-92(55-71(5)6)111(158)134-87(45-35-40-50-129)108(155)139-96(59-75(13)14)116(163)147-104(67-83(29)30)124(171)151-101(64-80(23)24)120(167)143-93(56-72(7)8)112(159)135-88(46-36-41-51-130)109(156)140-97(60-76(15)16)117(164)148-105(68-84(31)32)125(172)152-102(65-81(25)26)121(168)144-94(57-73(9)10)113(160)136-89(126(173)174)47-37-42-52-131;1-2(3)4/h69-105H,33-68,127-132H2,1-32H3,(H,133,157)(H,134,158)(H,135,159)(H,136,160)(H,137,153)(H,138,154)(H,139,155)(H,140,156)(H,141,165)(H,142,166)(H,143,167)(H,144,168)(H,145,161)(H,146,162)(H,147,163)(H,148,164)(H,149,169)(H,150,170)(H,151,171)(H,152,172)(H,173,174);1H3,(H,3,4)/t85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-;/m0./s1
SMILES Code
NCCCC[C@@H](C(O)=O)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.CC(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO.
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 2,529.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Jordan BK, Donn SM. Lucinactant for the prevention of respiratory distress syndrome in premature infants. Expert Rev Clin Pharmacol. 2013 Mar;6(2):115-21. doi: 10.1586/ecp.12.80. Review. PubMed PMID: 23473590. 2: Piehl E, Fernandez-Bustamante A. Lucinactant for the treatment of respiratory distress syndrome in neonates. Drugs Today (Barc). 2012 Sep;48(9):587-93. doi: 10.1358/dot.2012.48.9.1835160. Review. PubMed PMID: 23032799. 3: Donn SM, Sinha SK. Aerosolized lucinactant: a potential alternative to intratracheal surfactant replacement therapy. Expert Opin Pharmacother. 2008 Feb;9(3):475-8. doi: 10.1517/14656566.9.3.475 . Review. PubMed PMID: 18220497. 4: Donn SM. Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome. Expert Opin Investig Drugs. 2005 Mar;14(3):329-34. Review. PubMed PMID: 15833063. 5: Moen MD, Perry CM, Wellington K. Lucinactant: in neonatal respiratory distress syndrome. Treat Respir Med. 2005;4(2):139-45; discussion 146-7. Review. PubMed PMID: 15813666.